Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
Viking Therapeutics (VKTX) sell-off is unwarranted, "attractive opportunity to add" - Truist
-
Tesla's (TSLA) key Chinese rival BYD said to cut shifts as EV demand softens
-
Signature Bank assets taken over by New York Community Bancorp (NYCB), SVB still in limbo
-
Pfizer (PFE) snaps up Seagen (SGEN) in $43B deal, sees $10B revenue contribution in 2030
-
Northrop Grumman's (NOC) B-21 uncertainty "may cap valuation upside" - Cowen
-
Meta (META): Apple's privacy policy change 'no longer a drag on earnings', now a tailwind YoY - WSJ
-
Tesla (TSLA): Morgan Stanley on why the stock is up so much post Q4
-
eHealth (EHTH) raises Q4 guidance, shares soar
-
Five Below (FIVE): target raised at Oppenheimer on "outsized sales and EPS expansion"
-
Tesla (TSLA) Q4 preview by Morgan Stanley: margins, prices, guidance, demand
-
Dollar Tree (DLTR) taps ex-head of Dollar General as next CEO
-
Zoom (ZM): "limited risk reward at these levels", MKM Partners downgrades, lowers target
-
Boeing's (BA) FCF to benefit from high "re-sale values" for undelivered aircraft, analyst raises target
-
Spotify (SPOT) lays off 6% of staff, joins other tech companies making cuts
-
Coinbase (COIN) seen benefiting from credibility issues and Shanghai fork - J.P. Morgan raises target
-
Rivian's (RIVN) margins to remain negative, volume growth limited till 2026 - Deutsche Bank cuts target
-
Tesla (TSLA) can see 50%+ growth in 2023 - Piper Sandler bullish despite price cuts
-
Risk reward for Roblox (RBLX) "turned sharply negative" - Morgan Stanley downgrades, lowers target
-
Coinbase's (COIN) Positives Unnoticed, Long-term Position 'Stronger Than Ever' - Oppenheimer
-
Tesla (TSLA) target lowered at Mizuho on macro challenges, company remains 'long-term global EV leader'
-
Amazon (AMZN) cuts 18,000 jobs, exceeds projections
-
Coty (COTY) warranted "a higher valuation" on improved macro, Piper Sandler upgrades and raises target
-
Catalysts should drive Wynn's (WYNN) outperformance, Well Fargo upgrades and raises target
-
Starbucks (SBUX) 'poised to benefit from China’s reopening', target hiked at BofA
-
AMC (AMC) tanks on dilutive capital raise, proposed 1:10 reverse stock split, APE gains
-
CarMax (KMX) misses big on earnings, pauses stock buyback, shares plunge
-
Tesla (TSLA) rumored to prepare layoffs, shares trade higher
-
Twitter: 58% of Users Vote for Musk to Step Down as CEO
-
Ardelyx (ARDX) Kept at Neutral by Cantor Fitzgerald, "Need More Commercial Visibility"
-
Ardelyx (ARDX): FDA Will Have "Difficult Time Justifying Another Rejection" - Piper Sandler Bullish Post AdCom Vote
-
Tesla (TSLA) may soon have a new CEO, director claims
-
Poland's missile incident latest: Biden says rockets unlikely fired from Russia, Poland's Duda calls to invoke Article 4
-
Stray Russian rockets reportedly kill 2 in Poland, markets tank
-
Stifel Reiterates Biogen (BIIB) at Buy with $299 PT Following CEO Appointment
-
"Believe the FDA May Deny sabizabulin EUA" - Veru (VERU) PT Lowered at H.C. Wainwright
-
Veru (VERU): "See EUA More Likely Than Not " - Oppenheimer Reiterates Stock at Outperform, $36 PT
-
Veru (VERU): "See EUA More Likely Than Not " - Oppenheimer Reiterates Stock at Outperform, $36 PT
-
Why is Credit Suisse in Trouble? All You Need to Know
-
Ocugen's (OCGN) Intranasal Vaccine Deal 'Intriguing' - Mizuho Reiterates Stock at Buy
-
FedEx (FDX) PT Halved at Morgan Stanley, 'Numbers Need to Stop Falling First'
-
Costco's (COST) Value Proposition Unmatched, Stock Remains Top Pick - Analysts Bullish on COST Despite PT Cuts
-
Domino's (DPZ) Concerns Overblown and Already Priced In - Stock Upgraded at BMO Capital Markets
-
'This is Not a Bluff' - Russia's Putin to Mobilize 300,000 More Troops, Defense Names Jump
-
Intellia's (NTLA) NTLA-2002 and NTLA-2001 Data Continue to Validate Approach - Brookline Capital Bullish on Stock
-
Oppenheimer Reiterates Alnylam Pharmaceuticals (ALNY) at Outperform on Latest ALN-HSD Data
-
Outlook for sabizabulin Unchanged - Oppenheimer Defends Veru (VERU) Despite Weakness
-
Lucid Group (LCID) Files Massive Shelf Offering, Stock Slips Lower
-
Bristol Myers Squibb (BMY) Sliding on milvexian Readout, Analysts See Data as “Risky”
-
Bed Bath & Beyond (BBBY) Gains on Rumored Loan Deal, Company Yet to Confirm Details
-
Mt. Gox's Bitcoin Liquidation is Coming, Here's All You Need to Know

